SANGAMO THERAPEUTICS, INC — fact timeline

SANGAMO THERAPEUTICS, INC reported first quarter ended March 31, 2026 results: revenue $1.4 million, net income $31.0 million, EPS $0.08 per share.

“First Quarter 2026 Financial Results Consolidated net loss for the first quarter ended March 31, 2026 was $31.0 million, or $0.08 per share, compared to a consolidated net loss of $30.6 million, or $0.14 per share, for the same period in 2025. Revenues Revenues for the first quarter ended March 31, 2026 were $1.4 million, compared to $6.4 million for the same period in 2025.”

SANGAMO THERAPEUTICS, INC reported year ended December 31, 2025 results: revenue $39.6 million, net income $122.9 million, EPS $0.44 per share.

“For the year ended December 31, 2025, consolidated net loss was $122.9 million, or $0.44 per share, compared to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s exercise of its option to obtain a license pursuant to the terms of the 2008 licensing agreement for certain zinc finger modified cell lines, an increase of $1.0 million in revenue relating to our collaboration agreement with Astellas, and $0.4 million in revenue from research services relating to our capsid license agreement with Lilly, partially offset by $0.8 million in revenue relating to our collaboration agreement with Genentech recognized in 2024. Revenues were $39.6 million in 2025, compared to $57.8 million in 2024. The”

SANGAMO THERAPEUTICS, INC reported fourth quarter ended December 31, 2025 results: revenue $14.2 million, net income $37.4 million, EPS $0.11 per share.

“to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s”

SANGAMO THERAPEUTICS, INC issued 23,809,523 shares of common stock of warrant to investor in the Offering for reduced from $1.00 to $0.4719.

““Purchase Warrants” and together with the Pre-Funded Warrants, the “Warrants”). The combined offering price of each share of Common Stock and accompanying Purchase Warrant is $0.4719. The combined offering price of each Pre-Funded Warrant and accompanying Purchase Warrant is $0.4619. The Common Stock and Pre-Funded Warrants are being sold in combination with”

SANGAMO THERAPEUTICS, INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC valued at approximately $25.0 million (effective 2026-02-03).

“On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC”

SANGAMO THERAPEUTICS, INC received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).

“October 29, 2025, Sangamo Therapeutics, Inc. (the “Company”) received a letter (the “Extension Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to April 27, 2026, the bid price of the Company’s common”

SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“April 30, 2025 from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to cure the Minimum Bid Price Requirement by April 27, 2026, however if the Company does not regain compliance with the Minimum Bid Price Requireme”

SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 30, 2025, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance wi”

SANGAMO THERAPEUTICS, INC reported financial results for the quarter ended March 31, 2024.

“On May 9, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended March 31, 2024 (the “Press Release”).”

SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“April 24, 2024, Sangamo Therapeutics, Inc. (the “Company”) received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. In accordance with Nasd”

SANGAMO THERAPEUTICS, INC reported financial results for the year ended December 31, 2023.

“On March 13, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the year ended December 31, 2023 (the “Press Release”).”

SANGAMO THERAPEUTICS, INC: Added officer exculpation provision eliminating or limiting monetary liability for breach of fiduciary duty (effective 2023-06-02).

“an amendment of the Prior Restated Certificate to provide for the elimination or limitation of monetary liability of officers of the Company for breach of fiduciary duty pursuant to and consistent with the DGCL (the “Officer Exculpation Certificate”)”

SANGAMO THERAPEUTICS, INC: Increased authorized common stock from 320,000,000 to 640,000,000 shares (effective 2023-06-02).

“an amendment to the Seventh Amended and Restated Certificate of Incorporation, as amended (the “Prior Restated Certificate”), to increase the total number of shares of common stock authorized for issuance from 320,000,000 shares to 640,000,000 shares (the “Common Increase Certificate”)”

SANGAMO THERAPEUTICS, INC shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm.

“Proposal 7: Ratification of Appointment of Independent Registered Public Accounting Firm: For Against Abstain 135,630,865 4,026,854 1,890,901”

SANGAMO THERAPEUTICS, INC shareholders approved Approval of Amendment to Prior Restated Certificate to Reflect New Delaware Law Provisions Regarding Officer Exculpation.

“Proposal 6: Approval of Amendment to Prior Restated Certificate to Reflect New Delaware Law Provisions Regarding Officer Exculpation: For Against Abstain Broker Non-Votes 105,691,211 13,209,632 793,827 21,853,950”

SANGAMO THERAPEUTICS, INC shareholders approved Approval of Amendment to Prior Restated Certificate to Increase Authorized Number of Shares of Common Stock.

“Proposal 5: Approval of Amendment to Prior Restated Certificate to Increase Authorized Number of Shares of Common Stock: For Against Abstain 129,592,706 10,609,160 1,346,754”

SANGAMO THERAPEUTICS, INC shareholders approved Approval of the Amended 2018 Plan.

“Proposal 4: Approval of the Amended 2018 Plan: For Against Abstain Broker Non-Votes 107,945,255 11,334,715 414,700 21,853,950”

SANGAMO THERAPEUTICS, INC shareholders approved Approval, on an Advisory Basis, as to Whether the Advisory Stockholder Vote to Approve the Compensation of the Named Executive Officers Shall Occur Every Year, Once Every Two Years, or Once Every Three Years.

“Proposal 3: Approval, on an Advisory Basis, as to Whether the Advisory Stockholder Vote to Approve the Compensation of the Named Executive Officers Shall Occur Every Year, Once Every Two Years, or Once Every Three Years: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 114,444,618 586,929 3,759,057 904,066 21,853,950”

SANGAMO THERAPEUTICS, INC shareholders approved Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement.

“Proposal 2: Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement: For Against Abstain Broker Non-Votes 104,650,679 14,402,362 641,629 21,853,950”

SANGAMO THERAPEUTICS, INC shareholders approved Election of Directors.

“Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below: Name of Director For Against Abstain Broker Non-Votes Courtney Beers, Ph.D. 114,201,883 4,832,832 659,955 21,853,950 Robert F. Carey 113,101,718 5,922,892 670,060 21,853,950 Kenneth J. Hillan, M.B. 103,446,058 15,594,941 653,671 21,853,950 Margaret A. Horn, J.D. 113,858,717 5,170,548 665,405 21,853,950 Alexander D. Macrae, M.B., Ch.B., Ph.D. 113,360,223 5,647,730 686,717 21,853,950 John H. Markels, Ph.D. 107,674,614 11,367,958 652,098 21,853,950 James R. Meyers 113,376,518 5,642,044 676,108 21,853,950 H. Stewart Parker 95,877,540 23,150,147 666,983 21,853,950 Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. 113,656,657 5,427,258 610,755 21,853,950”

SANGAMO THERAPEUTICS, INC reported preliminary financial results for first quarter 2023.

“Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing preliminary financial results for the quarter ended March 31, 2023”

SANGAMO THERAPEUTICS, INC announced a restructuring with charges of approximately $5 million to $7 million affecting United States workforce and California internal manufacturing and allogeneic research footprints (approximately 120 roles in the United States, or approximately 27% of its United States workforce).

“in the elimination of approximately 120 roles in the United States, or approximately 27% of its United States workforce. Sangamo estimates that it will incur approximately $5 million to $7 million in cash-based expenses related to employee severance and notice period payments, benefits and related restructuring costs. Sangamo expects that the majority of the”

R. Andrew Ramelmeier was terminated as Executive Vice President, Technical Operations at SANGAMO THERAPEUTICS, INC.

“the employment of R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations, will terminate effective as of July 10, 2023.”

SANGAMO THERAPEUTICS, INC terminated Collaboration and License Agreement with Biogen MA, Inc. (effective 2023-06-15).

“On March 17, 2023, Biogen MA, Inc. and its affiliate, Biogen International GmbH (together, "Biogen") notified Sangamo of its termination for convenience, effective June 15, 2023 (the "Biogen Termination Date"), of the Collaboration and License Agreement (the "Biogen Agreement") by and between Biogen and Sangamo dated February 26, 2020”

SANGAMO THERAPEUTICS, INC terminated Collaboration and License Agreement with Novartis Institutes for BioMedical Research, Inc. (effective 2023-06-11).

“On March 13, 2023, Novartis Institutes for BioMedical Research, Inc. ("Novartis") notified Sangamo Therapeutics, Inc. ("Sangamo") of its termination for convenience, effective June 11, 2023 (the "Novartis Termination Date"), of the Collaboration and License Agreement (the "Novartis Agreement") by and between Novartis and Sangamo dated July 27, 2020”

SANGAMO THERAPEUTICS, INC reported financial results for the quarter and year ended December 31, 2022.

“On February 22, 2023, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022 (the “Press Release”).”

SANGAMO THERAPEUTICS, INC amended Amendment No. 2 to the Sales Agreement with Jefferies LLC valued at up to $175 million (effective 2022-12-23).

“On December 23, 2022, the Company and Jefferies entered into Amendment No. 2 to the Sales Agreement ("Amendment No. 2" and, together with the Sales Agreement, the "Amended Sales Agreement") to provide for an increase in the aggregate offering amount under the Sales Agreement such that the Company may offer and sell additional shares of Common Stock having an aggregate offering amount of up to $175 million”

SANGAMO THERAPEUTICS, INC: The Board approved and adopted the Fifth Amended and Restated Bylaws, effective immediately, making updates to stockholder meeting procedures, forum selection, indemnification, universal proxy rules, and other administrative revisions (effective 2022-12-15).

“On December 15, 2022, the Board, acting upon the recommendation of the Nominating Committee, approved and adopted an amendment and restatement of the Fourth Amended and Restated Bylaws of the Company (as so amended and restated, the “Fifth Amended and Restated Bylaws”), effective immediately.”

Margaret A. Horn was appointed as Director at SANGAMO THERAPEUTICS, INC.

“On December 15, 2022, the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Courtney Beers, Ph.D., and Margaret A. Horn to serve as directors of the Board until the Company’s next annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier deaths, resignations or removals.”

Courtney Beers was appointed as Director at SANGAMO THERAPEUTICS, INC.

“On December 15, 2022, the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Courtney Beers, Ph.D., and Margaret A. Horn to serve as directors of the Board until the Company’s next annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier deaths, resignations or removals.”

SANGAMO THERAPEUTICS, INC reported third quarter ended September 30, 2022 results: revenue 26.5 million, net income 53.2 million (net loss), EPS 0.34 per share (net loss).

“Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. Revenues Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021.”

Nathalie Dubois-Stringfellow was appointed as Senior Vice President, Head of Development at SANGAMO THERAPEUTICS, INC.

“Effective August 19, 2022, Nathalie Dubois-Stringfellow, Ph.D., currently serving as Senior Vice President, Product Development and Management, will assume the role of Senior Vice President, Head of Development of the Company.”

Rob Schott resigned as Senior Vice President, Head of Development at SANGAMO THERAPEUTICS, INC.

“On August 8, 2022, Rob Schott, M.D., M.P.H., F.A.C.C., Senior Vice President, Head of Development of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his resignation from this position and from his employment with the Company, with such resignation to be effective on August 19, 2022, in order to pursue a new opportunity.”

Saira Ramasastry departed as Director at SANGAMO THERAPEUTICS, INC.

“On March 28, 2022, Saira Ramasastry, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”) since June 2012, notified the Company of her decision not to stand for re-election at the Company’s annual meeting of stockholders to be held on May 24, 2022.”

Joseph S. Zakrzewski resigned as Director at SANGAMO THERAPEUTICS, INC.

“On November 17, 2021, Joseph S. Zakrzewski, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his voluntary resignation from the Board effective March 1, 2022.”

Gary H. Loeb resigned as Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at SANGAMO THERAPEUTICS, INC.

“On June 28, 2021, Gary H. Loeb, Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his resignation from these positions and from his employment with the Company, in each case to be effective on July 16, 2021, in order to pursue a new opportunity.”